Physician profile
Wayne Pharo
NPI 1144267378
$1,168.68
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $287 · 2021: $404.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $311.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $173.10 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $144.19 | 2019-2021 | |
| Pfizer INC. | $125.64 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $83.50 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.17 | 2019-2021 | |
| Abiomed | $59.52 | 2020 | |
| Novartis Pharmaceuticals Corporation | $44.62 | 2021 | |
| Arbor Pharmaceuticals, INC. | $41.68 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $32.87 | 2019 | |
| Esperion Therapeutics, INC. | $28.32 | 2021 | |
| Merck Sharp & Dohme LLC | $28.21 | 2021 | |
| United Therapeutics Corporation | $16.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Pharo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.